After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious ...
As part of its commitment to transparency, DMD published its 2024 Impact Report, detailing certified environmental performance, governance practices, and operational results aligned with SASB ...
CDMO giant Catalent inked a deal with Sarepta Therapeutics to manufacture what looks to become the first gene therapy to treat Duchenne muscular dystrophy (DMD). In November, the FDA gave its ...
Taiho Pharmaceutical’s investigational treatment for Duchenne muscular dystrophy (DMD) has failed to impact the time it takes patients to rise from the floor over 52 weeks, missing the phase 3 study’s ...
Pharmaceutical Technology on MSN
Santhera grants Agamree rights to Nxera for DMD
In October 2025, Health Canada approved Agamree from Santhera for the treatment of DMD in individuals aged four years and ...
Sarepta Therapeutics said it will update its prescribing information for Elevidys ® (delandistrogene moxeparvovec-rokl) after acknowledging the sudden death of a patient with Duchenne muscular ...
Duchenne muscular dystrophy (DMD) occurs as a result of genetic changes on the X chromosome. If someone has a gene change that can cause DMD, their children may inherit that change. DMD is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback